PK-EYE OVERVIEW
PK-EYE OVERVIEW
team
Chris Redhead
DR CHRISREDHEAD
CEO, Director & Co-founder
Following an early career as a cell biologist, Chris spent more than twelve years providing ranked life science equity research. He was a founder partner of the investment banking boutique Code Securities latterly Nomura Code. In the fifteen years since founding Aruwon, Chris has helped a host of Life Science SMEs manage all aspects of corporate and business development including fund raising and M&A.
SAHAR AWWAD
Sahar’s research background includes the delivery and development of biologics and small molecular weight drugs with particular knowledge in the overcoming the challenges in ocular drug delivery, in particular the vitreous and posterior segment of the eye. Sahar received her PhD in UCL, School of Pharmacy and UCL, Institute of Ophthalmology, where she continued her post-doctoral work.
CSO & Co - Founder
SAHAR AWWAD
Sahar has worked on various research projects that have resulted in the development of a novel in vitro model of the eye (the PK-Eye) along with various strategies for extending the duration of action of therapeutic proteins in the vitreous.
Sahar Awwad
DR YANN BOUREMEL
Yann is a biomedical engineer with strong interest in applied engineering to solve biomedical problems. He has experience in designing long term intraocular medical implants and in developing models to study physiological processes. He also has an extensive background in microfluidics, bench testing, instrument control, image visualisation techniques, data processing, modelling and rapid prototyping.
Fluid Biomedical Engineer Consultant
YANN BOUREMEL
He received his PhD in Fluid Mechanics in 2010 from King’s College London. He holds an MSc in Engineering (Diplome d'Ingénieur) from ENSTA ParisTech, an MSc in Fluid Mechanics from Paris VI, as well as Masters (Magistère) and BSc degrees in Physics from Paris VII.
MR BARRY BUTLER
Barry is an experienced leader with over 30 years of pharmaceutical experience. He held numerous management and executive positions at Glaxo, Inc. and Bausch & Lomb from 1988 until 2001. In 2001, Barry co-founded Acsentient, Inc., which was sold to Ista in 2002, resulting in the launch of Xibrom® and Istalol®. In 2004, Barry founded Sirion Therapeutics, Inc. a successful ophthalmic pharmaceutical company that developed and launched Durezol® and Zirgan®.
Director & Co-founder
BARRY BUTLER
Barry served as CEO of Sirion until its sale to Novartis in 2010. In 2010, Barry formed Point Guard Partners, LLC, which started and managed several ophthalmic pharmaceutical and services companies, including Revitalid, Inc., Kurobe Pharmaceuticals, Inc., and Oculos Clinical Research, LLC. Barry is currently the managing partner of BLP Management Group, a company that starts and manages ophthalmic focused biotechnology, pharmaceutical and medical device companies. Barry holds a bachelor’s degree in finance from The University of Alabama and a Master of Business Administration degree from City University of Seattle.
Barry Butler
Sahar Awwad
DR SAHAR AWWAD
Sahar has extensive knowledge in drug delivery and development of biologics and small molecular weight formulations, pharmaceutical technology, biotechnology and R&D. Sahar has experience in Life Sciences consultancy and project management with knowledge in therapeutics areas of ophthalmology, inflammation and infectious diseases. Sahar received her PhD in UCL, School of Pharmacy and UCL, Institute of Ophthalmology.
CSO & Co-founder
SAHAR AWWAD
Sahar has worked on various research projects that have resulted in the development of a novel in vitro model of the eye (the PK-Eye) along with various strategies for extending the duration of action of therapeutic proteins in the front and back of the eye. Sahar helps faciltate new technology and innovation focus leading to further expansion of the company's IP portfolio.